In Vitro Study of the Effect of Gadolinium Contrast on Fibrocytes

NCT02512796 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2015-07-31

No results posted yet for this study

Summary

Gadolinium contrast agents are frequently administered for MRI imaging. Very little is known of its toxicity outside of patients with reduced renal function.

Conditions

  • Gadolinium Toxicity

Interventions

DRUG

Gadolinium contrast dye

Gadolinium contrast dye administered during MRI

Sponsors & Collaborators

  • University of Virginia

    lead OTHER

Principal Investigators

  • Sundararaman Swaminathan, MD · University of Virginia

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02512796 on ClinicalTrials.gov